Closing the Gender Gap in Oncology Academic Leadership: Reshma Jagsi, MD, DPhil

​A recent study by Mudit Chowdhary, MD, and colleagues revealed that a substantial gender gap remains in academic oncology leadership: in a web query of 265 of the 273 accredited medical, radiation, and surgical oncology training programs, only 35.9% of faculty members were women. Representation was substantially lower among department chairs, with 21.7% of medical oncology programs, 11.7% of radiation oncology programs, and a mere 3.8% of surgical oncology programs chaired by women. In this int...
Continue reading

E-Cigarettes and Bladder Cancer Risk: Marc Bjurlin, DO, MSc

Despite their known pulmonary, neurological, and carcinogenic risks, electronic cigarette (e-cigarette) use has increased drastically in recent years, especially among adolescents and young adults. In a recent study, a team of researchers led by Marc Bjurlin, DO, MSc, Associate Professor of Urology at the University of North Carolina Chapel Hill's Lineberger Comprehensive Cancer Center, analyzed the urine samples of e-cigarette users and identified the presence of several carcinogenic biomarkers...
Continue reading

COVID-19 Risk in Cancer Patients: Melvin LK Chua, MBBS, FRCR, PhD, and Conghua Xie, MD, PhD

Last week, a research team under the direction of Conghua Xie, MD, PhD, and Melvin LK Chua, MBBS, FRCR, PhD, reported in JAMA Oncology that patients with cancer at a hospital in Wuhan, China, experienced an increased risk of COVID-19 infection relative to other members of the community. In this interview with i3 Health, Dr. Chua and Dr. Xie discuss their findings and analyze possible factors contributing to the increased risk of COVID-19 infection in patients with cancer. Can you comment on the ...
Continue reading

Head and Neck Cancer: Reducing In-Hospital Mortality With Eric Adjei Boakye, PhD

​Over 4% of head and neck cancer (HNC) patients who are hospitalized die during their stay in the hospital. How can this number be reduced? In a cross-sectional study recently published in JAMA Otolaryngology—Head and Neck Surgery, a research team led by Eric Adjei Boakye, PhD, found that among a variety of other patient- and hospital-related factors, male sex, weekend admissions, and treatment at nonteaching hospitals are associated with increased in-hospital mortality. In this interview with i...
Continue reading

Expanding Later-Line Treatment Options for Multiple Myeloma: Paul G. Richardson, MD

Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor. In this interview with i3 Health, Paul G. Richardson, MD, who served as the co-primary investigator of the ICARIA-MM study, on which the isatuximab approval was based, shares his thoughts on the si...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.